Skip to main content

Table 1 Baseline characteristics and NTRK3 promotor methylation status among all patients with CRC in validation cohort

From: Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer

Variables Total NTRK3 promotor methylation P value
Hypomethylation Hypermethylation
Age (median = 62 years)
 < 62 111 100 11  
 ≥ 62 118 103 15 0.504
Sex
 Female 100 88 12  
 Male 129 115 14 0.786
Tumor localization
 Colon 126 114 12  
 Rectum 103 89 14 0.334
Tumor size (median = 4.5 cm)
 < 4.5 104 90 14  
 ≥ 4.5 123 111 12 0.382
 Unknown 2    
Tumor differentiation
 High or moderate 191 168 23  
 Poor 38 35 3 0.584
Lymphovascular invasion
 No 210 188 22  
 Yes 17 13 4 0.219
 Unknown 2    
Perineural invasion
 No 208 183 25  
 Yes 19 18 1 0.611
 Unknown 2    
TNM stage
 I–II 143 123 20  
 III–IV 85 79 6 0.112
 Unknown 1    
CIMP
 Negative 222 198 24  
 Positive 7 5 2 0.145
Microsatellite status
 MSS 125 113 12  
 MSI 51 39 12 0.015
 Unknown 53    
KRAS
 Wild-type 119 110 9  
 Mutation 62 46 16 0.001
 Unknown 48    
BRAF
 Wild-type 174 151 23  
 Mutation 8 6 2 0.674
 Unknown 47    
Ki-67
 ≤ 25% 100 89 11  
 > 25% 84 72 12 0.502
 Unknown 45    
CA19-9
 ≤ 37 179 160 19  
 > 37 32 29 3 0.833
 Unknown 18    
CEA
 ≤ 5 158 138 20  
 > 5 57 54 3 0.122
 Unknown 14    
  1. CIMP: CpG island methylator phenotype; KRAS: kirsten rat sarcoma viral oncogene; BRAF: B-Raf proto-oncogene, serine/threonine kinase; Ki-67: kiel67 antigen; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen